Abstract
Background: As is well-known, serotonin-reuptake inhibitors (SRIs) are unsuccessful in management of forty to sixty percent of patients suffering from obsessivecompulsive disorder (OCD). So, purpose of the present trial was to assess that whether addon aripiprazole, as adjunctive to SRIs, is helpful in cases with treatment-resistant OCD.
Method: In an Open-prospective, single-arm interventional study with blinded rating, sixteen patients with OCD, who had not improved noticeably by serotonin-reuptake inhibitors, after maximum dosage and period, were allocated to get aripiprazole plus their SRIs for eight weeks. Management outcome was measured by means of the Yale-Brown Obsessive Compulsive Scale (YBOCS). Complete reaction to the abovementioned augmentative therapy was demarcated of at least fifty percent reduction in YBOCS’ score and partial reaction as equivalent to or >25% - <50% reduction in YBOCS in comparison with the starting point.
Results: Neither of patients responded with at least 25% decrease in YBOCS score to the aripiprazole addition (20 mg/day). 18% of cases experienced a reduction between 10-20%, and 68% of them less than 10%. Two patients did not show any change at all. The mean+/-SD baseline YBOCS’ score of 35.2 +/- 2.9 dropped to a mean of 32.8 +/- 4.1 at endpoint with a mean reduction of 8.8+/- 7.8% (p<0.06).
Conclusion: Within the limits of statistical power, this assessment does not offer additional proof that adding of aripiprazole to current SRI treatment could be worthwhile for cases suffering from treatment-resistant OCD.
Keywords: Antipsychotic, aripiprazole, obsessive-compulsive disorder, treatment resistant.
Current Psychopharmacology
Title:Aripiprazole Addition to Serotonin Reuptake Inhibitor in Treatment-Resistant Obsessive-Compulsive Disorder
Volume: 3
Author(s): Saeed Shoja Shafti
Affiliation:
Keywords: Antipsychotic, aripiprazole, obsessive-compulsive disorder, treatment resistant.
Abstract: Background: As is well-known, serotonin-reuptake inhibitors (SRIs) are unsuccessful in management of forty to sixty percent of patients suffering from obsessivecompulsive disorder (OCD). So, purpose of the present trial was to assess that whether addon aripiprazole, as adjunctive to SRIs, is helpful in cases with treatment-resistant OCD.
Method: In an Open-prospective, single-arm interventional study with blinded rating, sixteen patients with OCD, who had not improved noticeably by serotonin-reuptake inhibitors, after maximum dosage and period, were allocated to get aripiprazole plus their SRIs for eight weeks. Management outcome was measured by means of the Yale-Brown Obsessive Compulsive Scale (YBOCS). Complete reaction to the abovementioned augmentative therapy was demarcated of at least fifty percent reduction in YBOCS’ score and partial reaction as equivalent to or >25% - <50% reduction in YBOCS in comparison with the starting point.
Results: Neither of patients responded with at least 25% decrease in YBOCS score to the aripiprazole addition (20 mg/day). 18% of cases experienced a reduction between 10-20%, and 68% of them less than 10%. Two patients did not show any change at all. The mean+/-SD baseline YBOCS’ score of 35.2 +/- 2.9 dropped to a mean of 32.8 +/- 4.1 at endpoint with a mean reduction of 8.8+/- 7.8% (p<0.06).
Conclusion: Within the limits of statistical power, this assessment does not offer additional proof that adding of aripiprazole to current SRI treatment could be worthwhile for cases suffering from treatment-resistant OCD.
Export Options
About this article
Cite this article as:
Shoja Shafti Saeed, Aripiprazole Addition to Serotonin Reuptake Inhibitor in Treatment-Resistant Obsessive-Compulsive Disorder, Current Psychopharmacology 2014; 3 (3) . https://dx.doi.org/10.2174/221155600303150629162749
DOI https://dx.doi.org/10.2174/221155600303150629162749 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Use of Dexmedetomidine in Anesthesia and Intensive Care: A Review
Current Pharmaceutical Design Inhibition of Amyloid β Aggregation Using Optimized Nano-Encapsulated Formulations of Plant Extracts with High Metal Chelator Activities
Current Pharmaceutical Biotechnology Efficacy and Safety of Nonopioid Analgesics in Perioperative Pain Control
Current Drug Safety Retracted: Junk Food Consumption, Perceptions and Associated Factors among the Private School Children
Current Nutrition & Food Science Hypertension Impairs Cerebral Blood Flow in a Mouse Model for Alzheimer’s Disease
Current Alzheimer Research Cytoprotection and Immunomodulation in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Selective Fluorination in Drug Design and Development: An Overview of Biochemical Rationales
Current Topics in Medicinal Chemistry Basic Mechanisms Involved in the Anti-Cancer Effects of Melatonin
Current Medicinal Chemistry The Role of Melanocortin Peptides and Receptors in Regulation of Energy Balance
Current Pharmaceutical Design Hypertension in 2017: Update in Treatment and Pharmaceutical Innovations
Current Pharmaceutical Design The 21st Century Form of Vitamin E - Tocotrienol
Current Pharmaceutical Design A Hypothesis for Regenerative Therapy for Neuronal Disease: Stem Cells within Artificial Niche
Current Signal Transduction Therapy Adolescent Inpatients with Depression: Comparison to Inpatients without Depression and to Peers without Psychiatric Disorders
Adolescent Psychiatry The Epidemiology of Adiposity and Dementia
Current Alzheimer Research Genes, Blame and Loss of Control: is there a Place in Criminal Law for a ‘Genetic Defense’?
Recent Advances in DNA & Gene Sequences (Discontinued) Structural Bases for Substrate and Inhibitor Recognition by Matrix Metalloproteinases
Current Medicinal Chemistry Targeting Tumors Using Estrogen Receptor Ligand Conjugates
Current Cancer Drug Targets Vasoactive Factors and Diabetic Retinopathy: Vascular Endothelial Growth Factor, Cycoloxygenase-2 and Nitric Oxide
Current Pharmaceutical Design Therapeutic Interventions to Renin-Angiotensin-Aldosterone System, and Vascular Redox State
Recent Patents on Cardiovascular Drug Discovery α-Synuclein Ubiquitination and Novel Therapeutic Targets for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets